Skip to main content

Table 1 Basic clinical features of participants

From: PHLPP1 inhibits the growth and aerobic glycolysis activity of human ovarian granular cells through inactivating AKT pathway

 

Control

NA-PCOS

HA-PCOS

Age

31.9 ± 4.37

29.1 ± 3.20

31.1 ± 4.28

BMI (kg/m 2)

25.6 ± 2.63

26.5 ± 2.87

27.9 ± 4.06

Ferriman-Gallwey Score

3.13 ± 1.18

6.07 ± 1.33a

10.1 ± 1.49a, b

Total testosterone (nmol/L)

1.49 ± 0.21

2.03 ± 0.42a

3.16 ± 0.39a, b

SHBG (nmol/lL)

60.5 ± 2.20

54.1 ± 3.48a

45.4 ± 3.21a, b

FAI

2.46 ± 0.40

3.76 ± 0.83a

6.99 ± 0.99a, b

DHEAS (µmol/L)

3.46 ± 0.26

4.99 ± 0.25a

6.65 ± 0.32a, b

17-OHP (ng/ml)

0.93 ± 0.19

0.94 ± 0.32

1.10 ± 0.19

FSH (mIU/ml)

6.11 ± 0.26

5.91 ± 0.29

6.01 ± 0.32

LH (mIU/ml)

6.44 ± 0.31

8.47 ± 0.29a

11.4 ± 0.63a, b

TSH (µIU/ml)

2.05 ± 0.37

1.79 ± 0.28

1.91 ± 0.33

  1. BMI Body mass index, SHBG Sex hormone-binding globulin, FAI Free androgen index, DHEAS Dehydroepiandrosterone sulfate, 17-OHP 17-Hydroxyprogesterone, FSH Follicularstimulating hormone, LH Luteinizing hormone, TSH Thyroid-stimulating hormone 
  2. aSignificant difference between control and NA-PCOS or HA-PCOS subjects (p < 0.001)
  3. bSignificant difference between NA-PCOS and HA-PCOS subjects (p < 0.001)